A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® IFX Citation:

Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif.  P711 A pilot study using point of care testing for IFX and faecal calprotectin in IBD patients with a secondary loss of response.  Journal of Crohn’s and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838.

Highlight from this Publication

“…Using POC testing for IFX patients with a secondary LOR is clinically useful, correlates well with standardised testing, allows for immediate appropriate management of patients with low IFX trough and high FCP and results in a rapid clinical remission as early as 4 weeks. ”

BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US.  Not for use in diagnostic procedures in the US.

Health Canada License: 98838